QLGN Stock Overview
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Qualigen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$1.26 |
| 52 Week Low | US$0.28 |
| Beta | 0.062 |
| 1 Month Change | -25.94% |
| 3 Month Change | -40.28% |
| 1 Year Change | -68.56% |
| 3 Year Change | -98.65% |
| 5 Year Change | n/a |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?
Apr 05Qualigen nabs additional U.S. patent for ALAN anticancer platform
Dec 15Qualigen Therapeutics EPS misses by $0.61, misses on revenue
Nov 13Shareholder Returns
| QLGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.0% | 1.2% |
| 1Y | -68.6% | 0.7% | 24.9% |
Return vs Industry: QLGN underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: QLGN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| QLGN volatility | |
|---|---|
| QLGN Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QLGN's share price has been volatile over the past 3 months.
Volatility Over Time: QLGN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4 | Michael Poirier | www.qualigeninc.com |
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.
Qualigen Therapeutics, Inc. Fundamentals Summary
| QLGN fundamental statistics | |
|---|---|
| Market cap | US$1.87m |
| Earnings (TTM) | -US$12.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs QLGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$159.31k |
| Gross Profit | -US$159.30k |
| Other Expenses | US$12.32m |
| Earnings | -US$12.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -61.8% |
How did QLGN perform over the long term?
See historical performance and comparison